Cardiac Amyloidosis and Valvular Heart Disease

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Jan 11

PMID 38202228

Authors

Franz Duca

Christina Kronberger

Robin Willixhofer

Philipp E Bartko

Jutta Bergler-Klein

Christian Nitsche

Affiliations

Soon will be listed here.

Abstract

Growing interest has accrued in the co-existence of cardiac amyloidosis and valvular heart disease. Amyloid infiltration from either transthyretin (ATTR) or of light chain (AL) origin may affect any structure of the heart, including the valves. The recent literature has mainly focused on aortic stenosis and cardiac amyloidosis, improving our understanding of the epidemiology, diagnosis, treatment and prognosis of this dual pathology. Despite being of high clinical relevance, data on mitral/tricuspid regurgitation and cardiac amyloidosis are rather scarce and mostly limited to case reports and small cases series. It is the aim of this review article to summarize the current evidence of concomitant valvular heart disease and cardiac amyloidosis by including studies on epidemiology, diagnostic approaches, screening possibilities, therapeutic management, and prognostic implications.

Citing Articles

Dahou A, Awasthi V, Bkhache M, Djellal M, Yang X, Wang H J Clin Med. 2024; 13(21).

PMID: 39518498 PMC: 11546237. DOI: 10.3390/jcm13216359.

Amyloid and collagen templates in aortic valve calcification.

Jayaraman S, Narula N, Narula J, Gursky O Trends Mol Med. 2024; 30(11):1010-1019.

PMID: 38845326 PMC: 11563925. DOI: 10.1016/j.molmed.2024.04.015.

References

Treibel T, Fontana M, Gilbertson J, Castelletti S, White S, Scully P . Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement. Circ Cardiovasc Imaging. 2016; 9(8). DOI: 10.1161/CIRCIMAGING.116.005066. View

Binder C, Duca F, Stelzer P, Nitsche C, Rettl R, Aschauer S . Mechanisms of heart failure in transthyretin vs. light chain amyloidosis. Eur Heart J Cardiovasc Imaging. 2019; 20(5):512-524. DOI: 10.1093/ehjci/jey225. View

Aimo A, Camerini L, Fabiani I, Morfino P, Panichella G, Barison A . Valvular heart disease in patients with cardiac amyloidosis. Heart Fail Rev. 2023; 29(1):65-77. PMC: 10904406. DOI: 10.1007/s10741-023-10350-1. View

Nitsche C, Mascherbauer K, Wollenweber T, Koschutnik M, Dona C, Dannenberg V . The Complexity of Subtle Cardiac Tracer Uptake on Bone Scintigraphy. JACC Cardiovasc Imaging. 2022; 15(8):1516-1518. DOI: 10.1016/j.jcmg.2022.03.005. View

Treibel T, Lopez B, Gonzalez A, Menacho K, Schofield R, Ravassa S . Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients. Eur Heart J. 2017; 39(8):699-709. PMC: 5888951. DOI: 10.1093/eurheartj/ehx353. View

Chacko L, Karia N, Venneri L, Bandera F, Dal Passo B, Buonamici L . Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. Eur J Heart Fail. 2022; 24(9):1700-1712. PMC: 10108569. DOI: 10.1002/ejhf.2606. View

Chioncel O, Lainscak M, Seferovic P, Anker S, Crespo-Leiro M, Harjola V . Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017; 19(12):1574-1585. DOI: 10.1002/ejhf.813. View

Volz M, Pleger S, Weber A, Geis N, Hamed S, Mereles D . Initial experience with percutaneous mitral valve repair in patients with cardiac amyloidosis. Eur J Clin Invest. 2020; 51(6):e13473. DOI: 10.1111/eci.13473. View

Maurer M, Schwartz J, Gundapaneni B, Elliott P, Merlini G, Waddington-Cruz M . Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018; 379(11):1007-1016. DOI: 10.1056/NEJMoa1805689. View

10.

Nemes A, Foldeak D, Kormanyos A, Domsik P, Kalapos A, Borbenyi Z . Cardiac Amyloidosis Associated with Enlargement and Functional Impairment of the Mitral Annulus: Insights from the Three-Dimensional Speckle Tracking Echocardiographic MAGYAR-Path Study. J Heart Valve Dis. 2017; 26(3):304-308. View

11.

Jendroska K, Poewe W, Daniel S, Pluess J, Paulsen J, Barthel S . Ischemic stress induces deposition of amyloid beta immunoreactivity in human brain. Acta Neuropathol. 1995; 90(5):461-6. DOI: 10.1007/BF00294806. View

12.

Cammalleri V, Antonelli G, de Luca V, Carpenito M, Nusca A, Bono M . Functional Mitral and Tricuspid Regurgitation across the Whole Spectrum of Left Ventricular Ejection Fraction: Recognizing the Elephant in the Room of Heart Failure. J Clin Med. 2023; 12(9). PMC: 10178924. DOI: 10.3390/jcm12093316. View

13.

Gillmore J, Maurer M, Falk R, Merlini G, Damy T, Dispenzieri A . Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016; 133(24):2404-12. DOI: 10.1161/CIRCULATIONAHA.116.021612. View

14.

Topilsky Y, Maltais S, Inojosa J, Oguz D, Michelena H, Maalouf J . Burden of Tricuspid Regurgitation in Patients Diagnosed in the Community Setting. JACC Cardiovasc Imaging. 2018; 12(3):433-442. DOI: 10.1016/j.jcmg.2018.06.014. View

15.

Nitsche C, Mascherbauer K, Calabretta R, Koschutnik M, Dona C, Dannenberg V . Prevalence and Outcomes of Cardiac Amyloidosis in All-Comer Referrals for Bone Scintigraphy. J Nucl Med. 2022; 63(12):1906-1911. DOI: 10.2967/jnumed.122.264041. View

16.

Dona C, Nitsche C, Koschutnik M, Heitzinger G, Mascherbauer K, Kammerlander A . Unveiling Cardiac Amyloidosis, its Characteristics, and Outcomes Among Patients With MR Undergoing Transcatheter Edge-to-Edge MV Repair. JACC Cardiovasc Interv. 2022; 15(17):1748-1758. DOI: 10.1016/j.jcin.2022.06.009. View

17.

Benfari G, Antoine C, Miller W, Thapa P, Topilsky Y, Rossi A . Excess Mortality Associated With Functional Tricuspid Regurgitation Complicating Heart Failure With Reduced Ejection Fraction. Circulation. 2019; 140(3):196-206. DOI: 10.1161/CIRCULATIONAHA.118.038946. View

18.

Nitsche C, Aschauer S, Kammerlander A, Schneider M, Poschner T, Duca F . Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome. Eur J Heart Fail. 2020; 22(10):1852-1862. PMC: 7687139. DOI: 10.1002/ejhf.1756. View

19.

Nitsche C, Koschutnik M, Dona C, Radun R, Mascherbauer K, Kammerlander A . Reverse Remodeling Following Valve Replacement in Coexisting Aortic Stenosis and Transthyretin Cardiac Amyloidosis. Circ Cardiovasc Imaging. 2022; 15(7):e014115. DOI: 10.1161/CIRCIMAGING.122.014115. View

20.

Arshad S, Goldberg Y, Bhopalwala H, Dewaswala N, Miceli N, Birks E . High Prevalence of Cardiac Amyloidosis in Clinically Significant Aortic Stenosis: A Meta-Analysis. Cardiol Res. 2023; 13(6):357-371. PMC: 9822671. DOI: 10.14740/cr1436. View